Clinical trial · Observational
Biomarkers for Prediction of Tumor Response to Radiotherapy
Exploration of Potential Biomarkers to Predict Tumor Response to Radiotherapy in Patients With Solid Tumors
NCT03744819CI-TRIAL-00073679recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore potential biomarkers for prediction of therapeutic outcomes in patients with solid tumors after radiotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Expression status of biomarkers and their dynamic changes during treatment and follow-up
- timeFrame
- From the date of enrollment until the date of disease progression, assessed up to 3 years
- description
- Expression status of biomarkers and their dynamic changes in patients' biological specimens through the course of treatment and during follow-up as assessed by a variety of means, including RNA-seq, DNA-seq, RT-qPCR, IHC, WB and ELISA.
- measure
- Tumor short-term response to therapeutics
- timeFrame
- Within 1 month after the completion of radiotherapy
- description
- For patients treated with radiotherapy, shortly after the completion of treatment, the short-term response was assessed by using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) .
- measure
- Tumor long-term response to therapeutics
- timeFrame
- up to 3 years of follow-up
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Pathological proven diagnosis of solid tumors * Tumor accessible for biopsy during the course of radiotherapy or tumor samples could be obtained via surgery * Patient must provide study-specific informed consent prior to study entry Exclusion Criteria: * History of autoimmune diseases * History of immunotherapy * Prior radiation therapy that would result in overlap of planned radiation therapy fields * Will receive immunotherapy during the course of radiotherapy * Contraindications for biopsy, such as high bleeding risk
References
Publications (0)
Data not yet available
No reference posted for this study.